Dan Oppenheimer, Group Vice President, Development & Portfolio Strategy – BioMarin Pharmaceutical Inc, presented today at the Wells Fargo research conferences the actual state of art of BioMarin´s drugs under evaluation, including BMN-111.
Has said, BioMarin predicts to have results from the BMN-111 phase 2 on the second quarter of 2015.
BMN-111 is expected to have it´s final dosis between cohort 1) 2.5 microgram/kg and cohort 2) 7.5 microgram/kg.
To listen to the webcast here, (starting at minute 16).
Still a long road to travel.
Tagged: achondroplasia, Beyond Achondroplasia, biomarin, BMN-111, cohort, webcast, Wells Fargo
